Processing

Please wait...

Settings

Settings

1. WO2018224560 - INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION

Publication Number WO/2018/224560
Publication Date 13.12.2018
International Application No. PCT/EP2018/064920
International Filing Date 06.06.2018
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
15
Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
21
having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
30
Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
37
having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
38
having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
44
having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
63
Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
06
Antiasthmatics
C07C 311/21 (2006.01)
C07C 311/44 (2006.01)
A61K 31/63 (2006.01)
A61P 11/06 (2006.01)
CPC
C07C 311/21
C07C 311/44
C07C 323/62
Applicants
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) [FR/FR]; 101, Rue de Tolbiac 75013 PARIS, FR
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3, rue Michel Ange 75016 PARIS, FR
  • UNIVERSITE DE NANTES [FR/FR]; 1, quai de Tourville 44000 NANTES, FR
  • CHU NANTES [FR/FR]; DIRECTION GENERALE 5 allée de l'île Gloriette 44000 NANTES, FR
Inventors
  • SAUZEAU, Vincent; FR
  • LOIRAND, Gervaise; FR
  • LEBRETON, Jacques; FR
  • TESSIER, Arnaud; FR
  • QUEMENIER, Agnès; FR
Agents
  • BLOT, Philippe; FR
  • NEYRET, Daniel; FR
  • DOMENEGO, Bertrand; FR
  • HABASQUE, Etienne; FR
  • COLOMBIE, Damien; FR
  • HOLTZ, Béatrice; FR
Priority Data
17305662.306.06.2017EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION
(FR) INHIBITEURS DE RAC1 ET LEURS UTILISATIONS POUR INDUIRE UNE BRONCHODILATATION
Abstract
(EN)
The present invention concerns a compound having the following formula (I): wherein: - A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): - X is in particular chosen from the group consisting of: -SO2-N(R'b)-, R'b being H or a (C1-C6)alkyl group, -N(R"b)-SO2-, R"b being H or a (C1-C6)alkyl group, -CO-NH-, and -NH-CO-, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.
(FR)
La présente invention concerne un composé ayant la formule suivante (I) : dans laquelle : - A est en particulier -N(R'a)-C(=O)-R, R'a étant H ou un groupe alkyle en (C1-C6), et R étant de préférence un groupe ayant la formule suivante (II) : - X est particulièrement choisi dans le groupe constitué par : -SO2-N(R'b)-, R'b étant H ou un groupe alkyle en (C1-C6), -N(R"b)-SO2-, R"b étant H ou un groupe alkyle en (C1-C6), -CO-NH- et -NH-CO-. Le composé selon l'invention est destiné à être utilisé dans le traitement de pathologies caractérisées par une bronchoconstriction, telle que l'asthme.
Also published as
EP2018728642
Latest bibliographic data on file with the International Bureau